X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PFIZER - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PFIZER ASTRAZENECA PHARMA/
PFIZER
 
P/E (TTM) x 161.7 36.4 443.9% View Chart
P/BV x 25.1 5.4 468.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   PFIZER
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PFIZER
Mar-18
ASTRAZENECA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2852,365 54.3%   
Low Rs6341,625 39.0%   
Sales per share (Unadj.) Rs189.6430.3 44.1%  
Earnings per share (Unadj.) Rs-0.278.7 -0.3%  
Cash flow per share (Unadj.) Rs3.893.2 4.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs68.6586.5 11.7%  
Shares outstanding (eoy) m25.0045.75 54.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.6 109.2%   
Avg P/E ratio x-4,712.725.3 -18,591.7%  
P/CF ratio (eoy) x249.621.4 1,165.8%  
Price / Book Value ratio x14.03.4 410.9%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m23,98891,271 26.3%   
No. of employees `0001.62.6 59.3%   
Total wages/salary Rs m1,6053,143 51.1%   
Avg. sales/employee Rs Th3,040.27,484.8 40.6%   
Avg. wages/employee Rs Th1,029.21,195.0 86.1%   
Avg. net profit/employee Rs Th-3.31,369.1 -0.2%   
INCOME DATA
Net Sales Rs m4,74019,685 24.1%  
Other income Rs m921,143 8.1%   
Total revenues Rs m4,83220,828 23.2%   
Gross profit Rs m-1305,003 -2.6%  
Depreciation Rs m101663 15.3%   
Interest Rs m04 0.0%   
Profit before tax Rs m-1395,479 -2.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,878 0.3%   
Profit after tax Rs m-53,601 -0.1%  
Gross profit margin %-2.725.4 -10.8%  
Effective tax rate %-3.734.3 -10.7%   
Net profit margin %-0.118.3 -0.6%  
BALANCE SHEET DATA
Current assets Rs m2,72624,167 11.3%   
Current liabilities Rs m2,4359,544 25.5%   
Net working cap to sales %6.174.3 8.3%  
Current ratio x1.12.5 44.2%  
Inventory Days Days7455 133.9%  
Debtors Days Days4129 142.0%  
Net fixed assets Rs m1,0359,514 10.9%   
Share capital Rs m50458 10.9%   
"Free" reserves Rs m94226,375 3.6%   
Net worth Rs m1,71626,832 6.4%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,15636,900 11.3%  
Interest coverage xNM1,305.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.5 213.8%   
Return on assets %-0.19.8 -1.3%  
Return on equity %-0.313.4 -2.2%  
Return on capital %020.4 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37522 1,672.3%   
Fx outflow Rs m4701,489 31.6%   
Net fx Rs m-96-1,466 6.5%   
CASH FLOW
From Operations Rs m-83,318 -0.2%  
From Investments Rs m-146-2,383 6.1%  
From Financial Activity Rs m862-1,104 -78.1%  
Net Cashflow Rs m709-169 -420.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 4.9 320.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.7 38.4%  
Shareholders   12,856 85,207 15.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS